Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC) - Peeters, M; Oliner, K S; Price, T J (J Clin Oncol, 2014)
(3, Suppl):